StockWatch
·

Dodla Dairy Ltd

BSE: 543306

P/L Snapshot

Q1 FY27 · standalone

vs Q4 FY26·vs Q1 FY26
Revenue
967.62
+12.0%+4.1%
Expenditure
938.31
+12.8%+9.8%
Net Profit
21.75
-60.8%-65.1%
OPM %
3.54%
-0.28pp-3.29pp

Shareholding

Pattern breakdown

P/L Trends

(in crores)

RevenueExpenditureNet Profit
0.00270.93541.87812.801.1KQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27

Shareholding Trend

PromoterPublic
34%50%66%Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Price Chart
Latest News
Board Meeting25 Jul, 11:00 am

Dodla margins crushed: consolidated PAT down 35% YoY to ₹41 Cr as milk costs surge

Dodla Dairy's Q1 FY27 consolidated revenue rose 19.0% YoY to ₹1,197.94 Cr, but net profit fell 35.4% to ₹40.64 Cr (and 41.7% sequentially from ₹69.73 Cr), with net margin compressing to 3.4% from 6.1% a year ago. There were no exceptional items on either side, so raw and adjusted YoY profit growth are identical — the decline is entirely operational. The headline topline is also flattered by consolidation of HR Food Processing (effective Aug 2025), which management itself flags renders the YoY numbers non-comparable; standalone revenue grew just 6.1% to ₹955.66 Cr. The squeeze sits squarely on the raw-material line: consolidated cost of materials consumed jumped ~32% YoY to ₹940.61 Cr, far outpacing the 19% revenue rise, reflecting elevated milk procurement prices. The pain is starkest in the core standalone India business, where PAT collapsed 65% YoY to ₹21.75 Cr; overseas subsidiaries (₹210.28 Cr revenue, ₹18.23 Cr net profit) plus HR Food cushioned the group figure. That leaves a ~30-point gap between standalone (-65%) and consolidated (-35%) profit trends — readers should note the consolidated print understates how hard domestic dairy was hit. On the Q4 FY26 concall management guided to low-to-mid-teens FY27 revenue growth with a 50-100 bps gross-margin recovery as procurement costs normalized. Q1 delivers the topline (reported +19%, though inorganic; standalone +6% at the low end of the 8-9% organic India target) but decisively misses on margins — procurement costs rose rather than eased, directly contradicting the recovery thesis. No published street consensus for the quarter was found. Alongside results the board approved a ~2% minority stake in premium antibiotic-free D2C brand Sids Farm (FY26 turnover ₹240 Cr) for ₹11.65 Cr cash from internal accruals — immaterial to financials but consistent with the stated 'selective acquisitions' stance and a foothold in premium/D2C dairy. The earnings call is set for 27 July 2026.

25 Jul 2026, 11:00 am

Corporate Events

Board MeetingDODLA
2026
25Jul

Board Meeting

The meeting of the Board of Directors will be held to consid…

BSE Filing ↗
Board MeetingDODLA
2026
14Jul

Board Meeting

The 31st Annual General Meeting of the Company will be held …

BSE Filing ↗
DividendDODLA
2026
7Jul

₹5 / share

BSE Filing ↗
DividendDODLA
2026
7Jul

₹5 / share

BSE Filing ↗
Board MeetingDODLA
2026
16May

Board Meeting

The Board of Directors considered and approved the audited s…

BSE Filing ↗
Board MeetingDODLA
2024
23Oct

Board Meeting

Consider and approve Unaudited standalone and consolidated f…

BSE Filing ↗
Board MeetingDODLA
2024
18May

Board Meeting

Consider and approve Audited Standalone and Consolidated Fin…

BSE Filing ↗
Board MeetingDODLA
2024
27Jan

Board Meeting

Consider and approve Un-Audited Standalone and Consolidated …

BSE Filing ↗
Board MeetingDODLA
2023
21Oct

Board Meeting

Approval of Un-Audited Standalone and Consolidated Financial…

BSE Filing ↗